



1296 '00 SEP 15 P2 03

King & Spalding
Attention: Jess H. Stribling.
1730 Pennsylvania Ave. N.W.
Washington, D.C. 20006-4706

SEP - 9 2000

Docket No. 00P-1270/CP1

Dear Mr. Stribling:

This is in response to your petition filed on April 25, 2000, requesting permission to file an Abbreviated New Drug Application (ANDA) for the following drug products: Oxycodone Hydrochloride and Acetaminophen Tablets, 7.5 mg/325 mg and 10 mg/325 mg. The listed drug products to which you refer in your petition are Percocet® (Oxycodone Hydrochloride and Acetaminophen) Tablets, 7.5 mg/500 mg and 10 mg/650 mg manufactured by Endo Pharmaceuticals Inc.

Your request involves a change in strength for the acetaminophen component from that of the listed drug products (i.e., from Oxycodone Hydrochloride and Acetaminophen Tablets 7.5 mg/500 mg to 7.5 mg/325mg, and from Oxycodone Hydrochloride and Acetaminophen Tablets 10 mg/650mg to 10 mg/325 mg). The changes you request are the type of changes that are authorized under the Act.

We have reviewed your petition under Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (Act) and have determined that it is approved. This letter represents the Agency's determination that an ANDA may be submitted for the above-referenced drug products.

Under Section 505(j)(2)(C)(i) of the Act, the Agency must approve a petition seeking a strength which differs from the strength of the listed drug product unless it finds that investigations must be conducted to show the safety and effectiveness of the differing strength.

The Agency finds that the change in strength for the specific proposed drug products does not pose questions of safety or effectiveness because the uses, and route of administration of the proposed drug products are the same as that of the listed drug products. The Agency concludes, therefore, that investigations are not necessary in this instance. In addition, if shown to meet bioavailability requirements, the proposed drug product can be expected to have the same therapeutic effect as the listed reference drug product.

When an ANDA is submitted for your proposed drug products, the proposed labeling should reflect the maximum number of tablets per day that can be administered for your proposed drug

00P-1270

PAV/

products. The total daily dose of the acetaminophen component should not exceed the maximum total daily dose for adults of 4000 mg established by the Agency for its safe and effective range. Please refer to the Tentative Final Monograph for Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use (53 FR 46204, November 16, 1988).

The approval of this petition to allow an ANDA to be submitted for the above-referenced drug products does not mean that the Agency has determined that an ANDA will be approved for the drug products. The determination of whether an ANDA will be approved is not made until the ANDA itself is submitted and reviewed by the Agency.

To permit review of your ANDA submission, you must submit all information required under Sections 505(j)(2)(A) and (B) of the Act. To be approved, the drug products will, among other things, be required to meet current bioavailability requirements under Section 505(j)(2)(A)(iv) of the Act. We suggest that you submit your protocol to the Office of Generic Drugs, Division of Bioequivalence for these drug products prior to the submission of your ANDA. During the review of your application, the Agency may require the submission of additional information.

The listed drug products to which you refer in your ANDA must be the drug products upon which you based this petition. In addition, you should refer in your ANDA to the appropriate petition docket number cited above, and include a copy of this letter in the ANDA submission.

A copy of this letter approving your petition will be placed on public display in the Dockets Management Branch, Room 1061, Mail Stop HFA-305, 5630 Fishers Lane, Rockville, MD 20852.

Sincerely yours,



Gary J. Buehler
Acting Director
Office of Generic Drugs
Center for Drug Evaluation and Research